Ankit Mahadevia - 02 Feb 2024 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Role
Director
Signature
/s/ Tamara Joseph, Attorney-in-Fact for Ankit Mahadevia
Issuer symbol
SPRO
Transactions as of
02 Feb 2024
Net transactions value
-$87,399
Form type
4
Filing time
05 Feb 2024, 20:50:09 UTC
Previous filing
10 Oct 2023
Next filing
30 May 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Sale $87,399 -63,795 -7.9% $1.37 744,997 02 Feb 2024 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") that were granted to the Reporting Person on February 1, 2022 pursuant to a "sell to cover" provision included in the RSU Agreement.
F2 Represents the weighted average sales price per share. The shares sold at prices ranging from $1.36 to $1.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3 Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.